ABSTRACT
Daptomycin resistance (DAP(R)) in Staphylococcus aureus is associated with mutations in genes that are also implicated in staphylococcal pathogenesis. Using a laboratory-derived series of DAP exposed strains, we showed a relationship between increasing DAP MIC and reduced virulence in a Galleria mellonella infection model. Point mutations in walK and rpoC led to cumulative reductions in virulence and simultaneous increases in DAP MIC. A point mutation to mprF did not impact on S.aureus virulence; however deletion of mprF led to virulence attenuation and hyper-susceptibility to DAP. To validate our findings in G. mellonella, we confirmed the attenuated virulence of select isolates from the laboratory-derived series using a murine septicaemia model. As a corollary, we showed significant virulence reductions for clinically-derived DAP(R) isolates compared to their isogenic, DAP-susceptible progenitors (DAP(S)). Intriguingly, each clinical DAP(R) isolate was persistent in vivo. Taken together, it appears the genetic correlates underlying daptomycin resistance in S. aureus also alter pathogenicity.
Subject(s)
Anti-Bacterial Agents/pharmacology , Daptomycin/pharmacology , Staphylococcus aureus/drug effects , Staphylococcus aureus/pathogenicity , Aminoacyltransferases/genetics , Aminoacyltransferases/metabolism , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Drug Resistance, Multiple, Bacterial , Genotype , Larva/microbiology , Microbial Sensitivity Tests , Moths/microbiology , Phenotype , Point Mutation , Staphylococcus aureus/genetics , VirulenceSubject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Gram-Positive Bacteria/drug effects , Gram-Positive Bacterial Infections/drug therapy , Organophosphates/pharmacology , Organophosphates/therapeutic use , Oxazoles/pharmacology , Oxazoles/therapeutic use , Gram-Positive Bacterial Infections/microbiology , Humans , Oxazolidinones/pharmacology , Oxazolidinones/therapeutic useABSTRACT
Four dimeric sterol-polyamine conjugates have been synthesized from the homo- and hetero-connection of monomeric sterol-polyamine analogs in a head-to-tail manner. These dimeric conjugates show strong antibacterial activity against a broad spectrum of Gram-positive bacteria, whereas their corresponding activities against Gram-negative bacteria are relatively moderate. Though no significant difference was observed in the activities of these conjugates, cholic acid-containing dimeric conjugates generally exhibit higher activities than the corresponding deoxycholic acid-derived analogs. This is in contrast to the finding that a monomeric deoxycholic acid-spermine conjugate was more active than the corresponding cholic acid-derived analog.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Polyamines/chemistry , Sterols/chemistry , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Cholestanols/chemical synthesis , Cholestanols/chemistry , Cholestanols/pharmacology , Cholic Acid/chemistry , Deoxycholic Acid/analogs & derivatives , Dimerization , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Microbial Sensitivity Tests , Spermine/chemistry , Structure-Activity RelationshipABSTRACT
The genetic mechanisms that contribute to reduced susceptibility to vancomycin in Staphylococcus aureus are complex and heterogeneous. In addition, debate is emerging as to the true effect of reduced susceptibility to vancomycin on staphylococcal virulence. To investigate this, comparative genomics was performed on a collection of vancomycin-exposed isogenic S. aureus pairs (14 strains in total). Previously described mutations were observed in genes such as vraG, agrA, yvqF, and rpoB; however, a new mechanism was identified involving a serine/threonine phosphatase, Stp1. After constructing an stp1 deletion mutant, we showed that stp1 is important in vancomycin susceptibility and cell wall biosynthesis. Gene expression studies showed that stp1 also regulates virulence genes, including a hemolysin, superantigen-like protein, and phenol-soluble modulin, and that the deletion mutant is attenuated in virulence in vivo. Stp1 provides a new link between vancomycin susceptibility and virulence in S. aureus.
Subject(s)
Phosphoprotein Phosphatases/metabolism , Staphylococcus aureus/enzymology , Vancomycin Resistance , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Disease Models, Animal , Female , Gene Deletion , Gene Expression Profiling , Hemolysis , Histocytochemistry , Liver/pathology , Liver Abscess/microbiology , Liver Abscess/mortality , Liver Abscess/pathology , Mice , Mice, Inbred C57BL , Microbial Sensitivity Tests , Phosphoprotein Phosphatases/genetics , Staphylococcal Infections/microbiology , Staphylococcal Infections/mortality , Staphylococcal Infections/pathology , Staphylococcus aureus/drug effects , Staphylococcus aureus/pathogenicity , Survival Analysis , Virulence , Virulence Factors/genetics , Virulence Factors/metabolismABSTRACT
BACKGROUND: Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the genetic evolution to daptomycin resistance in S. aureus. METHODS: Whole genome sequencing was performed on a unique collection of isogenic, clinical (21 strains) and laboratory (12 strains) derived strains that had been exposed to daptomycin and developed daptomycin-nonsusceptibility. Electron microscopy (EM) and lipid membrane studies were performed on selected isolates. RESULTS: On average, six coding region mutations were observed across the genome in the clinical daptomycin exposed strains, whereas only two mutations on average were seen in the laboratory exposed pairs. All daptomycin-nonsusceptible strains had a mutation in a phospholipid biosynthesis gene. This included mutations in the previously described mprF gene, but also in other phospholipid biosynthesis genes, including cardiolipin synthase (cls2) and CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase (pgsA). EM and lipid membrane composition analyses on two clinical pairs showed that the daptomycin-nonsusceptible strains had a thicker cell wall and an increase in membrane lysyl-phosphatidylglycerol. CONCLUSION: Point mutations in genes coding for membrane phospholipids are associated with the development of reduced susceptibility to daptomycin in S. aureus. Mutations in cls2 and pgsA appear to be new genetic mechanisms affecting daptomycin susceptibility in S. aureus.
Subject(s)
Daptomycin/therapeutic use , Drug Resistance, Bacterial/genetics , Genome, Bacterial/drug effects , Staphylococcal Infections/microbiology , Staphylococcus aureus/genetics , Staphylococcus aureus/isolation & purification , Anti-Bacterial Agents/pharmacology , Cell Wall/chemistry , Cell Wall/drug effects , Cell Wall/metabolism , Daptomycin/pharmacology , Humans , Laboratories, Hospital , Lipid Metabolism/drug effects , Microbial Sensitivity Tests , Models, Biological , Patients , Sequence Analysis, DNA , Staphylococcus aureus/drug effectsABSTRACT
Fifty years ago methicillin-resistant Staphylococcus aureus (MRSA) first revealed themselves to the medical community, having been described in a landmark article published in the British Medical Journal. Among other things, their discovery set off a major response from the scientific and medical professions to control or even eliminate them as major human pathogens. Despite these efforts, however, MRSA have spread throughout the world and a half century after they burst upon the scene they continue to pose major challenges to research scientists and clinicians alike. In a very real sense, this year marks the 'birthday' of a remarkably successful pathogen. The major reasons for the ability of MRSA to prosper and cause disease in settings inimical to its survival form the basis of this article.
Subject(s)
Methicillin-Resistant Staphylococcus aureus/isolation & purification , Pandemics , Staphylococcal Infections/epidemiology , Staphylococcal Infections/history , Drug Resistance, Multiple, Bacterial , History, 20th Century , History, 21st Century , Humans , Staphylococcal Infections/microbiologySubject(s)
Anti-Bacterial Agents/therapeutic use , Fusidic Acid/therapeutic use , Skin Diseases, Bacterial/drug therapy , Clinical Trials as Topic , Drug Approval/legislation & jurisprudence , Gram-Positive Cocci/drug effects , Humans , Methicillin-Resistant Staphylococcus aureus/drug effects , Skin Diseases, Bacterial/microbiology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , United StatesSubject(s)
Methicillin-Resistant Staphylococcus aureus/isolation & purification , Sepsis/diagnosis , Staphylococcal Infections/diagnosis , Adult , Brain/diagnostic imaging , Chest Pain/etiology , Community-Acquired Infections/diagnosis , Fatal Outcome , Female , Furunculosis/microbiology , Furunculosis/therapy , Humans , Radiography, Thoracic , Sepsis/complications , Sepsis/microbiology , Shock/etiology , Staphylococcal Infections/complications , Staphylococcal Infections/microbiologyABSTRACT
Although there has been a relentless increase in resistance to antimicrobial agents amongst important bacterial pathogens throughout the world, it is well known that the number of new antimicrobial agents being brought to the market has undergone a steady decline in the past several decades. There are a number of reasons for this, which are detailed in this article, but there is also a great deal of continuing research to find new effective antimicrobials, much of it now being carried out in academic centres and especially in small biotechnology companies, rather than by large pharma. Whilst classic screening methods and chemical modification of known antimicrobial agents continue to produce potential leads for new antimicrobial agents, a number of other approaches are being investigated. These include the search for potentiators of the activity of known antimicrobial agents and the development of hybrid agents, novel membrane-active drugs, and inhibitors of bacterial virulence and pathogenesis. A number of new bacterial targets are also being exploited, as are bacteriophages and their lytic enzymes. Given the amount of investigation presently underway, it is clear that although the antibiotic pipeline is not as promising as it was half a century ago, it is far from dry.
Subject(s)
Anti-Infective Agents/pharmacology , Drug Discovery/trendsSubject(s)
Drug Resistance, Bacterial , Enterobacteriaceae/enzymology , beta-Lactamases , Animals , Drug Resistance, Bacterial/genetics , Enterobacteriaceae/genetics , Enterobacteriaceae/pathogenicity , Humans , Klebsiella pneumoniae/enzymology , Swine/microbiology , beta-Lactam Resistance/genetics , beta-Lactamases/genetics , beta-Lactamases/isolation & purification , beta-Lactamases/physiologyABSTRACT
Complicated skin and skin structure infections (cSSSIs) continue to pose a significant clinical challenge. The most frequent cause of these infections is Staphylococcus aureus, although other organisms, including Streptococcus pyogenes and, in certain circumstances, Enterobacteriaceae, are also involved. The relentless increase in methicillin resistance among S. aureus isolated in hospitals throughout the world has made it important to provide coverage for these organisms when treating cSSSIs in hospitals. More recently, however, there has been a striking increase in methicillin resistance among staphylococci isolated from infections acquired in the community, particularly in the USA. As a result, previous recommendations for empirical therapy of these important infections are now outdated. The papers in this Supplement detail the properties of a new broad-spectrum cephalosporin that has activity against MRSA and is, thus, an outstanding candidate for empirical therapy of cSSSIs. The papers included provide data on the in vitro activity, pharmacokinetics and pharmacodynamics as well as the clinical efficacy of ceftaroline fosamil, which is a welcome addition to our therapeutic armamentarium against cSSSIs.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Cephalosporins/therapeutic use , Methicillin-Resistant Staphylococcus aureus/drug effects , Skin Diseases, Bacterial/drug therapy , Soft Tissue Infections/drug therapy , Staphylococcal Skin Infections/drug therapy , Anti-Bacterial Agents/pharmacology , Cephalosporins/pharmacology , Clinical Trials, Phase III as Topic , Drug Resistance, Bacterial , Humans , Practice Guidelines as Topic , Randomized Controlled Trials as Topic , Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/microbiology , Soft Tissue Infections/diagnosis , Soft Tissue Infections/microbiology , Staphylococcal Skin Infections/diagnosis , Staphylococcal Skin Infections/microbiology , CeftarolineABSTRACT
With the current high prevalence of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) strains but in light of the general belief that beta-lactam antibiotics are more effective than vancomycin against infections caused by methicillin-susceptible S. aureus (MSSA) isolates, clinicians may utilize antistaphylococcal penicillins in combination with vancomycin for the empirical treatment of S. aureus infections. Vancomycin is considered to kill MSSA more slowly than oxacillin. Thus, we sought to evaluate the interaction of the combination of oxacillin and vancomycin on bacterial killing in vitro. Ten clinical isolates of MSSA isolated in the year 2000 were investigated. The killing observed at 24 h by vancomycin at 20 microg/ml, oxacillin at 16 microg/ml, or the combination did not differ (approximately 2.5 to 3.5 log10 CFU/ml). In a separate experiment, we assessed bacterial killing in a dynamic model simulating the free plasma concentration profiles expected following the administration of a combination of vancomycin at 1 g every 12 h and oxacillin at 1 g every 6 h. The time-kill profiles of these regimens against S. aureus ATCC 29213 were comparable to those observed in the fixed-concentration experiments. Using these methods, we found no evidence that vancomycin antagonized the bactericidal effect of oxacillin or that there was any benefit from use of the combination.
Subject(s)
Anti-Bacterial Agents/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Oxacillin/pharmacology , Vancomycin/pharmacology , Anti-Bacterial Agents/pharmacokinetics , Drug Antagonism , Drug Synergism , Microbial Sensitivity Tests , Oxacillin/pharmacokinetics , Vancomycin/pharmacokineticsABSTRACT
Recently, we [E.M.C. D'Agata, G.F. Webb, M.A. Horn, R.C. Moellering Jr., and S. Ruan, Modellingthe invasion of community-acquired methicillin-resistant Staphylococcus aureus into the hospital setting, Clin. Infect. Dis. 48 (2009), pp. 274284] proposed a deterministic mathematical model to characterize the factors contributing to the replacement of hospital-acquired methicillin-resistant Staphylococcus aureus(HA-MRSA) with the community-acquired MRSA (CA-MRSA) and to quantify the effectiveness of interventionsaimed at limiting the spread of CA-MRSA in the hospital setting. Numerical simulations of the model strongly suggest that CA-MRSA will become the dominant MRSA strain in the hospital setting. In this companion paper, we provide steady-state analysis and more numerical simulations of the model. It is shown that when no colonized or infected patients enter the hospital, competitive exclusion of HA-MRSA by CA-MRSA will occur with increased severity of CA-MRSA infections resulting in longer hospitalizations and a larger in-hospital reservoir of CA-MRSA. Improving compliance with hand hygiene and decolonization of CA-MRSA carriers are effective control strategies.
Subject(s)
Community-Acquired Infections/microbiology , Cross Infection/microbiology , Hospitals , Methicillin-Resistant Staphylococcus aureus/physiology , Basic Reproduction Number , Community-Acquired Infections/epidemiology , Computer Simulation , Cross Infection/epidemiology , Hospitalization/statistics & numerical data , Hospitals/statistics & numerical data , Humans , Models, BiologicalABSTRACT
Vancomycin is a commonly used antibiotic due to its effectiveness in treating serious gram-positive infections caused by methicillin-resistant Staphylococcus aureus. As commercial drug assays and a multitude of pharmacokinetic data from a variety of patient populations are widely available, therapeutic monitoring of serum vancomycin concentrations is frequently performed by clinicians, with the expectation that targeting the concentrations within a relatively narrow range can minimize toxicity yet still achieve therapeutic success. Much debate exists, however, over the value of routine therapeutic monitoring of vancomycin levels because of conflicting evidence regarding the ability of serum concentrations to predict effectiveness or prevent toxicity. In addition, studies have suggested that the potential for nephrotoxicity or ototoxicity with vancomycin monotherapy is minimal at conventional dosages of 1 g (15 mg/kg) every 12 hours. However, increased rates of nephrotoxicity have recently been reported with doses of 4 g/day or higher. The American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists published a consensus statement on therapeutic monitoring of serum vancomycin levels in adults. These organizations established an expert panel to review the scientific data and controversies associated with vancomycin monitoring and to make recommendations based on the available evidence. As the members of this panel, we summarize the conclusions and highlight the recommendations from the consensus statement. We determined that the area under the concentration-time curve (AUC): minimum inhibitory concentration (MIC) ratio is the most useful pharmacodynamic parameter to predict vancomycin effectiveness and suggested a target ratio of 400 or greater to eradicate S. aureus. In addition, trough serum concentration monitoring is the most accurate and practical method to monitor vancomycin serum levels. Increasing trough concentrations to 15-20 mg/L to attain the target AUC:MIC ratio may be desirable but is currently not supported by clinical trials. Alternative therapies should be considered in patients with S. aureus infections that demonstrate a vancomycin MIC of 2 mg/L or greater because the target AUC:MIC ratio ( 400) is unlikely to be achieved in this setting. Increasing the dosage to result in higher trough concentrations may increase the potential for toxicity; however additional clinical experience is required to determine the extent.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Practice Guidelines as Topic , Staphylococcal Infections/drug therapy , Vancomycin/therapeutic use , Adult , Area Under Curve , Clinical Trials as Topic , Drug Monitoring , Humans , Microbial Sensitivity Tests , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Vancomycin Resistance/drug effectsABSTRACT
BACKGROUND: Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally related, methicillin-susceptible S. aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancomycin susceptibility in MSSA is similar to that seen in MRSA. METHODS: Differences in vancomycin population analysis profiles; chemical autolysis; vancomycin, oxacillin, and daptomycin minimum inhibitory concentrations; and bactericidal activities were examined. RESULTS: Progressive vancomycin resistance correlated with increasing daptomycin nonsusceptibility. Chemical autolysis and the bactericidal activity of vancomycin, oxacillin, and daptomycin were reduced in the final, vancomycin-intermediate S. aureus isolate, compared with the vancomycin-susceptible MSSA progenitor. CONCLUSIONS: Clinicians should recognize that reduced vancomycin susceptibility can occur in S. aureus irrespective of background methicillin susceptibility and that development of intermediate vancomycin susceptibility in MSSA may result in increased tolerance to several classes of anti-staphylococcal antibiotics.
Subject(s)
Anti-Bacterial Agents/pharmacology , Staphylococcus aureus/drug effects , Vancomycin Resistance , Vancomycin/pharmacology , Bacteriolysis , Colony Count, Microbial , Daptomycin/pharmacology , Humans , Microbial Sensitivity Tests , Microbial Viability , Octoxynol/toxicity , Oxacillin/pharmacology , Staphylococcal Infections/microbiology , Staphylococcus aureus/classification , Staphylococcus aureus/isolation & purificationABSTRACT
Practice guidelines for therapeutic monitoring of vancomycin treatment for Staphylococcus aureus infection in adult patients were reviewed by an expert panel of the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. A literature review of existing evidence regarding vancomycin dosing and monitoring of serum concentrations, in addition to patient outcomes combined with expert opinion regarding the drug's pharmacokinetic, pharmacodynamic, and safety record, resulted in new recommendations for targeting and adjustment of vancomycin therapy.